Cover Image
市場調查報告書

端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49) :開發中產品分析

Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 364832
出版日期 內容資訊 英文 107 Pages
訂單完成後即時交付
價格
Back to Top
端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49) :開發中產品分析 Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Pipeline Review, H1 2016
出版日期: 2016年06月28日 內容資訊: 英文 107 Pages
簡介

本報告提供以端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49) 為標的之治療藥開發相關資訊,提供您開發階段,藥物標的,作用機制,給藥途徑及各分子類型分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49)概要

治療藥的開發

端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49):開發中的產品 - 各開發階段

端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49):開發中的產品 - 各治療範圍

端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49):開發中的產品 - 各適應症

端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49):企業開發中的產品

端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49):大學/機關開發中的產品

端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49):治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49)治療藥的開發企業

  • Adamis Pharmaceuticals Corporation
  • Argos Therapeutics, Inc.
  • Asterias Biotherapeutics, Inc.
  • e-Therapeutics Plc
  • F. Hoffmann-La Roche Ltd.
  • Inovio Pharmaceuticals, Inc.
  • Invectys SA
  • Johnson & Johnson
  • Komipharm International Co., Ltd.
  • Mediolanum farmaceutici S.p.A.
  • Ultimovacs AS
  • Vaxon Biotech

藥物簡介

端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49):暫停中的計劃

端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49):開發中止的產品

端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49):主要消息與新聞稿

附錄

目錄
Product Code: GMDHC0051TDB

Summary

Global Markets Direct's, 'Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Pipeline Review, H1 2016', provides in depth analysis on Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) targeted pipeline therapeutics.

The report provides comprehensive information on the Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49)
  • The report reviews Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Overview
  • Therapeutics Development
    • Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Products under Development by Stage of Development
    • Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Products under Development by Therapy Area
    • Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Products under Development by Indication
  • Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Products under Development by Companies
  • Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Products under Development by Universities/Institutes
  • Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Companies Involved in Therapeutics Development
    • Adamis Pharmaceuticals Corporation
    • Argos Therapeutics, Inc.
    • Asterias Biotherapeutics, Inc.
    • e-Therapeutics Plc
    • F. Hoffmann-La Roche Ltd.
    • Inovio Pharmaceuticals, Inc.
    • Invectys SA
    • Johnson & Johnson
    • Komipharm International Co., Ltd.
    • Mediolanum farmaceutici S.p.A.
    • Ultimovacs AS
    • Vaxon Biotech
  • Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Drug Profiles
    • ASTVAC-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASTVAC-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ETS-2300 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Telomerase for Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Telomerase for Alzheimer's Disease and Atherosclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Telomerase for Aplastic Anemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GX-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • imetelstat sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INO-1400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INO-5400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INVAC-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KML-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rocapuldencel-T - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target Telomerase for Lung Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Telomerase for ALS, GVHD, Ageing and Leukemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TeloB-VAX - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tertomotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UCPVax - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UV-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target Telomerase for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target Telomerase for Solid Tumor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vbx-016 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vbx-026 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vx-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vx-006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Dormant Projects
  • Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Discontinued Products
  • Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Featured News & Press Releases
    • Jun 13, 2016: Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 in Metastatic Renal Cell Carcinoma Following Interim Data Review
    • May 02, 2016: Asterias Biotherapeutics Announces Oral Presentation at ASGCT 19th Annual Meeting
    • Apr 20, 2016: Geron Announces Two Imetelstat Poster Presentations at the American Association for Cancer Research Annual Meeting
    • Mar 23, 2016: Argos Therapeutics Announces Initiation of a Phase 2 Clinical Trial of AGS-003 for the Treatment of Non-small Cell Lung Cancer in Combination with Standard-of-Care Chemotherapy
    • Mar 02, 2016: New trial launched to test cancer vaccine
    • Feb 24, 2016: Asterias Biotherapeutics Announces Successful End-of-Phase 2 Meeting with FDA for AST-VAC1
    • Jan 21, 2016: Asterias Biotherapeutics Announces Completion of Transfer of AST-VAC2 Manufacturing Process to Cancer Research UK as Milestone Towards Initiating Phase 1/2 Clinical Trial
    • Jan 14, 2016: Geron Announces Initiation of Janssen Phase 2/3 Clinical Trial of Imetelstat in Myelodysplastic Syndromes
    • Dec 10, 2015: Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 for Metastatic Renal Cell Carcinoma Following Second Planned Interim Analysis
    • Nov 05, 2015: Geron Announces Presentations at American Society of Hematology Annual Meeting
    • Nov 05, 2015: Janssen to Present Posters on Imetelstat at the 2015 American Society of Hematology Annual Meeting
    • Oct 30, 2015: Invectys starts the third dose level of its phase I clinical trial evaluating INVAC-1, an innovative anti-cancer therapeutic vaccine
    • Sep 16, 2015: Geron Announces Initiation of Janssen Phase 2 Clinical Trial of Imetelstat in Myelofibrosis
    • Sep 02, 2015: Dual Publications in the New England Journal of Medicine Highlight Transformative Potential of Imetelstat in Hematologic Myeloid Malignancies
    • Aug 10, 2015: Argos Therapeutics Announces Pilot Clinical Trial of AGS-003 as Neoadjuvant Immunotherapy for Localized Renal Cell Carcinoma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Adamis Pharmaceuticals Corporation, H1 2016
  • Pipeline by Argos Therapeutics, Inc., H1 2016
  • Pipeline by Asterias Biotherapeutics, Inc., H1 2016
  • Pipeline by e-Therapeutics Plc, H1 2016
  • Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Pipeline by Inovio Pharmaceuticals, Inc., H1 2016
  • Pipeline by Invectys SA, H1 2016
  • Pipeline by Johnson & Johnson, H1 2016
  • Pipeline by Komipharm International Co., Ltd., H1 2016
  • Pipeline by Mediolanum farmaceutici S.p.A., H1 2016
  • Pipeline by Ultimovacs AS, H1 2016
  • Pipeline by Vaxon Biotech, H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Dormant Projects (Contd..2), H1 2016
  • Dormant Projects (Contd..3), H1 2016
  • Discontinued Products, H1 2016
  • Discontinued Products (Contd..1), H1 2016
  • Discontinued Products (Contd..2), H1 2016
  • Discontinued Products (Contd..3), H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top